MMP3 and sarcopenia: In a subsequent study, univariate analysis observed that male sex, old age, glucocorticoid use > 5 mg/day, high levels of MMP3, and higher disability evaluated by the Health Assessment Questionnaire (HAQ) were associated with sarcopenia (defined by AWGS) development at 2 years in RA patients [28].